阅读说明：本技术 Egcg在制备预防病原细菌感染的制剂或食品中的应用 (Application of EGCG in preparation of preparation or food for preventing pathogenic bacterial infection ) 是由 卫林 韩晓阳 陈悦 杨洋 于 2020-06-29 设计创作，主要内容包括：本发明涉及EGCG在制备预防病原细菌感染的制剂或食品中的应用。本发明要求保护表没食子儿茶素没食子酸酯(EGCG)在制备预防病原细菌感染的制剂或食品中的应用。本发明公开了EGCG对病原细菌感染的预防功能和作用机制,为EGCG的抗感染药物研发提供新方向。(The invention relates to an application of EGCG in preparing a preparation or food for preventing pathogenic bacterial infection. The invention claims the application of epigallocatechin gallate (EGCG) in preparing a preparation or food for preventing pathogenic bacterial infection. The invention discloses a prevention function and an action mechanism of EGCG on pathogenic bacteria infection, and provides a new direction for research and development of EGCG anti-infective drugs.)

1. Application of epigallocatechin gallate in preparing preparation or food for preventing pathogenic bacteria infection is provided.

2. Use according to claim 1, characterized in that: pathogenic bacteria include gram-positive and/or gram-negative bacteria.

3. Use according to claim 1 or 2, characterized in that: the pathogenic bacteria include one or more of Escherichia coli ATCC25922, Acinetobacter baumannii ATCC19606, Staphylococcus aureus ATCC25923 and methicillin-resistant Staphylococcus aureus MRSA.

4. Use according to claim 1, characterized in that: the pathogenic bacteria infected part is abdominal cavity.

5. Use according to claim 1, characterized in that: the preparation is a medicament, and the medicament is an injection.

6. Use according to claim 5, characterized in that: the single dose of the injection is 1-10 mg/kg/day.

7. Use according to claim 1, characterized in that: the food is health food or beverage.

8. Use according to claim 1, characterized in that: the epigallocatechin gallate is used for reducing bacterial load at an infection part.

9. Use according to claim 1, characterized in that: the epigallocatechin gallate is used for promoting chemotactic migration of neutrophils, monocytes and macrophages to an infected site.

10. Use according to claim 9, characterized in that: the epigallocatechin gallate induces macrophages in abdominal cavities of mice to produce cytokines and chemokines by activating macrophage innate immunity related cell signaling pathways.

Technical Field

The invention relates to the technical field of bacterial infection prevention, in particular to application of EGCG in preparation of a preparation or food for preventing pathogenic bacterial infection.

Background

Since green tea is rich in various natural active substances, the physiological and pharmacological functions of green tea have been receiving attention for a long time. Tea polyphenols (the general term for all polyphenols in green tea) are the main water-soluble components in tea, are considered as important substances for green tea to exert physiological and pharmacological functions, and are the first botanical drugs approved by the U.S. food and drug administration for marketing. In tea polyphenols, catechin compound accounts for about 60-80%, wherein Epigallocatechin gallate (EGCG) is the highest component in catechin, and accounts for about 50% -60% of catechin compound. Known studies have shown that EGCG has a variety of biological activities, including in particular: antibacterial, antiviral, arteriosclerosis resisting, thrombosis resisting, blood vessel proliferation resisting, antiinflammatory, antitumor, free radical scavenging, and oxidative damage reducing effects, but has no toxicity to normal tissue and cell.

At present, many experiments show that EGCG has a broad-spectrum antibacterial function, can inhibit infection of gram-positive bacteria and gram-negative bacteria, and has an inhibiting effect on staphylococcus aureus, salmonella typhi, shigella dysenteriae, cholera bacillus, pseudomonas aeruginosa, bacillus subtilis, oral streptococcus mutans and the like, so that EGCG has a good application prospect in research and development of anti-infection biological medicines and functional foods. To summarize, the major mechanisms currently found for EGCG to inhibit bacterial infection are: (1) acting on the cell membrane of bacteria, EGCG can combine with the cell membrane of bacteria to destroy the wall membrane structure of bacteria, thereby inhibiting the growth of bacteria; (2) acting on a biofilm formed by bacteria, wherein the biofilm formed by the bacteria is one of key factors causing chronic infection, and recent research shows that EGCG can inhibit the formation of the bacterial biofilm so as to inhibit the infection of the bacteria; (3) the drug resistance protein acting on bacteria, methicillin resistance of staphylococcus aureus is mainly mediated by mecA gene, the gene codes penicillin binding protein 2a (PBP2a), and EGCG can inhibit the generation of PBP2a to play a role in bacteriostasis. In view of the above, scientists focus on the therapeutic effect of EGCG on pathogenic bacterial infection, and current research shows that EGCG has a direct inhibitory effect on bacteria or bacterial pathogenic agents, thereby inhibiting bacterial infection.

However, is EGCG a major active ingredient of green tea for daily drinking by people, and has a function of preventing pathogenic bacterial infection? The existing studies have not been elucidated.

The study on the prevention and treatment effects of epigallocatechin gallate on the bladder epithelial infection caused by escherichia coli, and Liu Bing discloses the prevention effect of EGCG on the bladder epithelial infection caused by escherichia coli, but the prevention effect of bacterial infection in the study is realized by inhibiting bladder epithelial cell injury caused by escherichia coli infection and inhibiting inflammatory reaction caused by escherichia coli infection, the function of preventing pathogenic bacterial infection by regulating and controlling body background immunity of EGCG is not disclosed, and the influence of advanced intervention of EGCG on bacterial load is not disclosed.

Disclosure of Invention

In order to solve the technical problems, the invention aims to provide an application of EGCG in preparation of a preparation or food for preventing pathogenic bacterial infection.

The invention aims to disclose application of epigallocatechin gallate (EGCG) in preparation of a preparation or food for preventing pathogenic bacterial infection.

Furthermore, epigallocatechin gallate is derived from green tea.

Further, pathogenic bacteria include gram-positive and/or gram-negative bacteria.

Further, the pathogenic bacteria include one or more of Escherichia coli ATCC25922, Acinetobacter baumannii ATCC19606, Staphylococcus aureus Aureus ATCC25923, and methicillin-resistant Staphylococcus aureus MRSA.

Further, the site of infection with pathogenic bacteria is the abdominal cavity.

Further, the preparation is a medicament, and the medicament is an injection.

Further, the single dose of the injection is 1-10 mg/kg/day.

Further, the food is a health food or a beverage.

Further, epigallocatechin gallate is used to reduce bacterial load at the site of infection.

Further, epigallocatechin gallate is used to promote chemotactic migration of neutrophils, monocytes and macrophages to the site of infection.

Furthermore, epigallocatechin gallate induces mouse peritoneal macrophages to produce cytokines and chemokines through the activation of macrophage innate immunity related cell signaling pathway.

Further, EGCG induces the mouse peritoneal macrophages to generate certain levels of cytokines and chemokines by activating the phosphorylation of the mouse peritoneal macrophages p38 and JNK.

By the scheme, the invention at least has the following advantages:

the invention clarifies that the main active ingredient of the green tea, namely EGCG, can effectively enhance the immunity of the organism from the angle of regulating the innate immune pattern of the organism by the EGCG, thereby reducing the risk of the organism being infected by pathogenic bacteria, and the prevention effect of the EGCG on the pathogenic bacteria infection is obviously better than the treatment effect, thereby providing a new direction for the research and development of the anti-infective medicament of the EGCG.

In addition, from the perspective of homology of medicine and food, the application of EGCG in developing foods for preventing pathogenic bacterial infection is prompted, the understanding of people on the health function, pharmacological function and mechanism of products (such as green tea and the like) containing EGCG is expanded, and theoretical basis is provided for the research and development of the health function of the products containing EGCG and health products related to green tea.

The foregoing description is only an overview of the technical solutions of the present invention, and in order to make the technical solutions of the present invention more clearly understood and to implement them in accordance with the contents of the description, the following description is made with reference to the preferred embodiments of the present invention and the accompanying detailed drawings.

Drawings

FIG. 1 shows the results of bacterial load tests of different experimental groups after infection of the abdominal cavity with different pathogenic bacteria;

FIG. 2 is a cell ratio map and a cell absolute map statistical result of the local neutrophilic granulocytes, monocytes and macrophages in the abdominal cavity after EGCG is injected into the abdominal cavity;

FIG. 3 shows the results of measurements of local cytokine and chemokine levels in the abdominal cavity after intraperitoneal injection of EGCG;

FIG. 4 is a (A) Westernblot graph and (B) grayscale value statistical graph of phosphorylation of p38 and JNK of EGCG-activated mouse peritoneal macrophages;

in fig. 1-4, ns indicates no significant difference, p <0.05, p <0.01, p < 0.001.

Detailed Description

The following examples are given to further illustrate the embodiments of the present invention. The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.